84 related articles for article (PubMed ID: 25312469)
1. AlphaScreen selectivity assay for β-catenin/B-cell lymphoma 9 inhibitors.
Zhang M; Wisniewski JA; Ji H
Anal Biochem; 2015 Jan; 469():43-53. PubMed ID: 25312469
[TBL] [Abstract][Full Text] [Related]
2. Analysis of the interaction of BCL9 with beta-catenin and development of fluorescence polarization and surface plasmon resonance binding assays for this interaction.
Kawamoto SA; Thompson AD; Coleska A; Nikolovska-Coleska Z; Yi H; Wang S
Biochemistry; 2009 Oct; 48(40):9534-41. PubMed ID: 19715304
[TBL] [Abstract][Full Text] [Related]
3. Optimizations of a novel fluorescence polarization-based high-throughput screening assay for β-catenin/LEF1 interaction inhibitors.
Chen Y; Fu Z; Li D; Yue Y; Liu X
Anal Biochem; 2021 Jan; 612():113966. PubMed ID: 32956692
[TBL] [Abstract][Full Text] [Related]
4. New homogeneous high-throughput assays for inhibitors of β-catenin/Tcf protein-protein interactions.
Zhang M; Huang Z; Yu B; Ji H
Anal Biochem; 2012 May; 424(1):57-63. PubMed ID: 22370279
[TBL] [Abstract][Full Text] [Related]
5. Discovery of 1-Benzoyl 4-Phenoxypiperidines as Small-Molecule Inhibitors of the β-Catenin/B-Cell Lymphoma 9 Protein-Protein Interaction.
Li Z; Zhang M; Teuscher KB; Ji H
J Med Chem; 2021 Aug; 64(15):11195-11218. PubMed ID: 34270257
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of β-catenin/B cell lymphoma 9 protein-protein interaction using α-helix-mimicking sulfono-γ-AApeptide inhibitors.
Sang P; Zhang M; Shi Y; Li C; Abdulkadir S; Li Q; Ji H; Cai J
Proc Natl Acad Sci U S A; 2019 May; 116(22):10757-10762. PubMed ID: 31088961
[TBL] [Abstract][Full Text] [Related]
7. Discovery of 2-(3-(3-Carbamoylpiperidin-1-yl)phenoxy)acetic Acid Derivatives as Novel Small-Molecule Inhibitors of the β-Catenin/B-Cell Lymphoma 9 Protein-Protein Interaction.
Wang Z; Zhang M; Luo W; Zhang Y; Ji H
J Med Chem; 2021 May; 64(9):5886-5904. PubMed ID: 33902288
[TBL] [Abstract][Full Text] [Related]
8. Structure-Based Optimization of Small-Molecule Inhibitors for the β-Catenin/B-Cell Lymphoma 9 Protein-Protein Interaction.
Zhang M; Wang Z; Zhang Y; Guo W; Ji H
J Med Chem; 2018 Apr; 61(7):2989-3007. PubMed ID: 29566337
[TBL] [Abstract][Full Text] [Related]
9. Design of triazole-stapled BCL9 α-helical peptides to target the β-catenin/B-cell CLL/lymphoma 9 (BCL9) protein-protein interaction.
Kawamoto SA; Coleska A; Ran X; Yi H; Yang CY; Wang S
J Med Chem; 2012 Feb; 55(3):1137-46. PubMed ID: 22196480
[TBL] [Abstract][Full Text] [Related]
10. High-Throughput Selectivity Assays for Small-Molecule Inhibitors of β-Catenin/T-Cell Factor Protein-Protein Interactions.
Zhang M; Catrow JL; Ji H
ACS Med Chem Lett; 2013 Feb; 4(2):306-11. PubMed ID: 24900664
[TBL] [Abstract][Full Text] [Related]
11. Fusion of the BCL9 HD2 domain to E1A increases the cytopathic effect of an oncolytic adenovirus that targets colon cancer cells.
Fuerer C; Homicsko K; Lukashev AN; Pittet AL; Iggo RD
BMC Cancer; 2006 Oct; 6():236. PubMed ID: 17020613
[TBL] [Abstract][Full Text] [Related]
12. Crystal structure of a beta-catenin/BCL9/Tcf4 complex.
Sampietro J; Dahlberg CL; Cho US; Hinds TR; Kimelman D; Xu W
Mol Cell; 2006 Oct; 24(2):293-300. PubMed ID: 17052462
[TBL] [Abstract][Full Text] [Related]
13. E-cadherin is required for caveolin-1-mediated down-regulation of the inhibitor of apoptosis protein survivin via reduced beta-catenin-Tcf/Lef-dependent transcription.
Torres VA; Tapia JC; Rodriguez DA; Lladser A; Arredondo C; Leyton L; Quest AF
Mol Cell Biol; 2007 Nov; 27(21):7703-17. PubMed ID: 17785436
[TBL] [Abstract][Full Text] [Related]
14. A microtiter assay for quantifying protein-protein interactions associated with cell-cell adhesion.
Graham NA; Pope MD; Rimchala T; Huang BK; Asthagiri AR
J Biomol Screen; 2007 Aug; 12(5):683-93. PubMed ID: 17507638
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis and biological evaluation of quercetin derivatives as novel β-catenin/B-cell lymphoma 9 protein-protein interaction inhibitors.
Shen LA; Peng X; Bao Y; Liu C; Zhang H; Li J; Zhu D; Zhang Q
Eur J Med Chem; 2023 Feb; 247():115075. PubMed ID: 36599228
[TBL] [Abstract][Full Text] [Related]
16. Development of a novel fluorescence polarization-based assay for studying the β-catenin/Tcf4 interaction.
Tian W; Xu Y; Han X; Duggineni S; Han X; Huang Z; An J
J Biomol Screen; 2012 Apr; 17(4):530-4. PubMed ID: 22127421
[TBL] [Abstract][Full Text] [Related]
17. Recent advances in β-catenin/BCL9 protein-protein interaction inhibitors.
Zhang H; Bao Y; Liu C; Li J; Zhu D; Zhang Q
Future Med Chem; 2021 May; 13(10):927-940. PubMed ID: 33849283
[TBL] [Abstract][Full Text] [Related]
18. Expression of E-cadherin and β-catenin in two cholangiocarcinoma cell lines (OZ and HuCCT1) with different degree of invasiveness of the primary tumor.
Abuetabh Y; Persad S; Nagamori S; Huggins J; Al-Bahrani R; Sergi C
Ann Clin Lab Sci; 2011; 41(3):217-23. PubMed ID: 22075503
[TBL] [Abstract][Full Text] [Related]
19. An intrinsically labile α-helix abutting the BCL9-binding site of β-catenin is required for its inhibition by carnosic acid.
de la Roche M; Rutherford TJ; Gupta D; Veprintsev DB; Saxty B; Freund SM; Bienz M
Nat Commun; 2012 Feb; 3():680. PubMed ID: 22353711
[TBL] [Abstract][Full Text] [Related]
20. beta-catenin is involved in N-cadherin-dependent adhesion, but not in canonical Wnt signaling in E2A-PBX1-positive B acute lymphoblastic leukemia cells.
Nygren MK; Døsen-Dahl G; Stubberud H; Wälchli S; Munthe E; Rian E
Exp Hematol; 2009 Feb; 37(2):225-33. PubMed ID: 19101069
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
